First clinical study of the selective 5-HT3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache

E G Couturier, R Hering, C A Foster, T J Steiner, F Clifford Rose

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Granisetron (BRL 43694), a selective 5-HT3 receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but 1 patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.

Original languageEnglish
Pages (from-to)296-7
Number of pages2
JournalHeadache
Volume31
Issue number5
Publication statusPublished - May 1991

Cite this

Couturier, E. G., Hering, R., Foster, C. A., Steiner, T. J., & Clifford Rose, F. (1991). First clinical study of the selective 5-HT3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache. Headache, 31(5), 296-7.